Results 51 to 60 of about 96,485 (242)

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard   +6 more
wiley   +1 more source

Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery

open access: yesВопросы современной педиатрии, 2023
Background. Psoriasis is an independent risk factor for cardiovascular diseases (CVD). One of the markers associated with the CVD course is epicardial fatty tissue (EFT) that is thicker in psoriasis patients.
Leyla S. Namazova-Baranova   +7 more
doaj   +1 more source

Understanding European cross-border cooperation: a framework for analysis [PDF]

open access: yes, 2012
European integration has had a dual impact on border regions. On the one hand, borders were physically dismantled across most of the EU’s internal territory.
Aron R.   +15 more
core   +1 more source

Clinical Efficacy and Safety of Topical Roflumilast in Psoriasis: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Traditional first‐line topical treatments for plaque psoriasis, particularly corticosteroids and vitamin D analogs, frequently have only limited efficacy for long‐term use, and present difficulties with safety and adherence. Objectives In this systematic review and meta‐analysis of randomized controlled trials (RCTs), we assessed ...
Aimal A. Khattak   +11 more
wiley   +1 more source

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study [PDF]

open access: yes, 2013
Objectives: To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA).<p></p> Methods Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to ...
Beutler, A.   +10 more
core   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin   +6 more
wiley   +1 more source

Pengaruh Suplementasi Vitamin D Terhadap Perubahan Skor Psoriasis Area and Severity Index (PASI) Pada Pasien Psoriasis: Studi Kasus Dengan Pendekatan Berbasis Bukti

open access: yesJurnal Ilmu Kesehatan Indonesia
Latar Belakang: Psoriasis merupakan suatu penyakit autoimun dan inflamasi kulit yang bersifat kronis. Perjalanan penyakit psoriasis membuat kualitas hidup pasien menurun dan meningkatkan mortalitas. Vitamin D memiliki peran penting dalam fungsi kekebalan
Anni Rahmawati, Wiji Lestari
doaj   +1 more source

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

open access: yes, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M   +3 more
core  

Sahlberg, P. (2011). Finnish lessons: what can the world learn from educational change in Finland?. New York: Teachers College Press. [Book review] [PDF]

open access: yes, 2011
Book review of: Sahlberg, P. (out in November 2011). Finnish lessons: What can the world learn from educational change in Finland?. New York: Teachers College Press.
Franko, Anja
core   +2 more sources

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Home - About - Disclaimer - Privacy